Umbralisib Plus Ibrutinib Response Rates in Mantle Cell Lymphoma and CLL
The transcript for this video contains no spoken or captioned content beyond music and applause cues, so no theoretical content is available to extract from the source material itself. Based solely on the title, the subject concerns combination targeted-therapy theory in hematologic oncology: the clinical response rates achieved when umbralisib (a PI3K/casein kinase-1 epsilon inhibitor) is combined with ibrutinib (a Bruton's tyrosine kinase inhibitor) in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia (CLL), within the domain of B-cell malignancy pharmacotherapy.
Umbralisib Plus Ibrutinib Response Rates in Mantle Cell Lymphoma and CLL
The transcript for this video contains no spoken or captioned content beyond music and applause cues, so no theoretical content is available to extract from the source material itself. Based solely o…